Engineered nanoparticles carrying immunostimulatory oligonucleotides has been confirmed to synergize with anti-CTLA-4 therapy to achieve tumor suppression in animal models of melanoma, colon cancer, and breast cancer [161]. The gene discussed is CTLA4; the disease is neoplasm.